 IRVINE, Calif., Nov. 13, 2020 GLOBE NEWSWIRE -- Inari Medical, Inc. NASDAQ: NARI Inari, a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced follow-up results of the first 230 patients enrolled in its FLASH study. FLASH is a real world registry to study the FlowTriever system in intermediate- and high-risk pulmonary embolism PE patients. The results were strongly positive. Just one death 0.4 was reported at 30 days. By contrast, the national PERT Consortium Quality Database recently showed 30-day mortality rates of 25.9 and 6.1 for high- and intermediate-risk PE patients. In addition, the FLASH Registry showed a readmission rate of 6.7, compared to the nearly 25 readmission rate shown in the PERT Database. Efficacy data were equally compelling, showing normalization or near normalization in a battery of hemodynamic variables like pulmonary artery pressure, RVLV ratio, and heart rate, as well as dyspnea shortness of breath metrics. 